

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

PE/Dazzle(TM) 594 anti-mouse/human CD11b

RRID:AB_2563647

Type: Antibody

Proper Citation

BioLegend Cat# 101255, RRID:AB_2563647

Antibody Information

URL: http://antibodyregistry.org/AB_2563647

Proper Citation: BioLegend Cat# 101255, RRID:AB_2563647

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Dazzle(TM) 594 anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_2563647

Vendor: BioLegend

Catalog Number: 101255

Alternative Catalog Numbers: 101256

Record Creation Time: 20231110T035214+0000

Record Last Update: 20260829T103126+0000

Ratings and Alerts

No rating or validation information has been found for PE/Dazzle(TM) 594 anti-mouse/human CD11b.

No alerts have been found for PE/Dazzle(TM) 594 anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shane J, et al. (2026) Genetically engineered eye-colonizing microbes that deliver the anti-inflammatory cytokine interleukin-10 enhance corneal tissue repair. *Cell reports*, 45(3), 117064.

Abdelfattah N, et al. (2026) Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma. *Cancer cell*, 44(4), 760.

Brosius SN, et al. (2026) Identification of CD74-positive antigen presenting glioma cells in primary human tumors and murine models of NF1 high-grade glioma. *Molecular cancer therapeutics*.

Chen M, et al. (2026) Nano-granulated zoledronate sensitizes innate immune metabolism to enhance vaccine-induced and antitumor immunity. *Cell reports. Medicine*, 7(5), 102765.

Young RE, et al. (2025) Disruption of E-cadherin in the airway led to dysplastic stressed cells and asthma-like phenotypes. *Developmental cell*.

Mahat DB, et al. (2025) Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. *Immunity*, 58(7), 1688.

Gastaldi T, et al. (2025) Multi-omics and functional characterization of the tumor-killing capacity of Imiquimod-activated plasmacytoid dendritic cells. *iScience*, 28(6), 112670.

Nagaraju GP, et al. (2024) Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. *Cell reports. Medicine*, 101881.

Mahat DB, et al. (2024) Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer. *bioRxiv : the preprint server for biology*.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. *Cancer cell*, 41(2), 235.

Liu Y, et al. (2023) A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression. *Developmental cell*, 58(23), 2700.

Kim AS, et al. (2021) Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. *Cell*, 184(17), 4414.

Keerthivasan S, et al. (2021) Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1. *Immunity*, 54(7), 1511.

Park JG, et al. (2021) Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. *iScience*, 24(9), 102941.

Tong HI, et al. (2016) Physiological function and inflamed-brain migration of mouse monocyte-derived macrophages following cellular uptake of superparamagnetic iron oxide nanoparticles-Implication of macrophage-based drug delivery into the central nervous system. *International journal of pharmaceutics*, 505(1-2), 271.